RxDoctor Payments Data

Garrett Roy

Psychiatric/Mental Health · Beaumont, TXNPI 1407108715

Payments from drug & device makers

$1,216in general payments, 2019–2025

Across 53 payments — averaging $22.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$416
  • Alkermes, Inc.$262
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$151
  • AbbVie$103
  • Otsuka America Pharmaceutical, Inc.$79
  • Neurocrine Biosciences, Inc.$68
  • plus $137 from 4 others

What the payments were for

  • Food & beverage$1,15995%
  • Education$575%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,216 in reported general payments places this provider in the 65th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$2,215,540
Medicare patients
897
Services billed
9,725

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine45$233,856
IngrezzaValbenazine Tosylate12$95,098
EliquisApixaban94$73,931
AustedoDeutetrabenazine11$58,050
VraylarCariprazine Hcl38$55,977
Invega SustennaPaliperidone Palmitate13$33,910
FanaptIloperidone12$28,599
LybalviOlanzapine/Samidorphan Malate11$17,152
JardianceEmpagliflozin22$15,762
EntrestoSacubitril/Valsartan19$15,490
Risperdal ConstaRisperidone Microspheres22$14,867
TrulicityDulaglutide14$14,497
XareltoRivaroxaban15$13,500
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$13,185
MyrbetriqMirabegron22$10,552

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo$416$291,90556 claims
Neurocrine Biosciences, Inc.Ingrezza$68$95,09812 claims
AbbVieVraylar, Linzess$103$63,80550 claims
Vanda Pharmaceuticals Inc.Fanapt$42$28,59912 claims
Alkermes, Inc.Lybalvi$262$17,15211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Beaumont

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →